Loading organizations...
NextVivo develops advanced immune organoid technology, creating three-dimensional, holistic models of healthy and diseased human tissues. This platform incorporates all key immune cell types and their functional interactions, providing a more accurate representation of in vivo conditions. The company's innovative approach leverages human cells to build immune-competent organoids, offering a sophisticated tool for biological research and drug discovery that moves beyond traditional two-dimensional cell cultures.
The company was founded in 2021 by Mark Davis, Calvin Kuo, and Adam Margolin. Established in Stanford Research Park, NextVivo emerged from an understanding of the critical need for more physiologically relevant human disease models. The founders envisioned a way to harness breakthrough organoid technology to better replicate complex biological systems, addressing limitations in preclinical drug development processes.
NextVivo's technology is primarily utilized by pharmaceutical and biotechnology companies seeking to accelerate the development of novel drugs and cell therapies. Their immune organoid platform aids in identifying and validating drug candidates, particularly for complex conditions like cancer and infectious diseases. The long-term vision is to significantly enhance the efficiency and success rate of drug development, ultimately leading to more effective treatments for a wide range of human illnesses.
NextVivo has raised $8.0M across 1 funding round.
NextVivo has raised $8.0M in total across 1 funding round.
NextVivo has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $8M Seed | — | Abstract Ventures, Alumni Ventures, Andreessen Horowitz, Atomic, DFJ Growth, DST Global, General Catalyst, Khosla Ventures, Menlo Ventures, Quiet Capital, ZhenFund, Eric Ries, Jeffrey LEE, Marc Benioff, Othman Laraki | Announced |
NextVivo is a biotechnology company that develops an immune organoid technology platform to accelerate the development of safer and more effective therapies. Their platform creates three-dimensional (3D) models of healthy and diseased human tissues that incorporate key immune cell types and interactions, enabling the generation and testing of cell and antibody therapies for diseases such as cancer, infections, and autoimmune disorders. This technology serves pharmaceutical companies and researchers by providing immune-competent human-derived models to improve drug discovery and clinical trial biomarker strategies. Founded in 2021 and based in Palo Alto, California, NextVivo is gaining momentum with significant early-stage funding led by Khosla Ventures and others, positioning it at the forefront of immune-oncology and immunotherapy innovation[1][2][5].
NextVivo was co-founded by Drs. Mark Davis and Calvin Kuo from Stanford University, along with Dr. Adam Margolin, a former Chair and Professor at Mount Sinai. The idea emerged from their research on immune system interactions within tissues, leading to the development of organoids that better replicate physiological immune responses than previous models. Early traction includes licensing technology from Stanford and securing $7.9 million in seed funding to advance their platform and expand applications across oncology, infectious diseases, and autoimmune disorders[2][1].
NextVivo is riding the wave of precision immunotherapy and organoid technology, which are transforming drug discovery by enabling personalized and immune-competent models for testing therapies. The timing is critical as pharmaceutical companies increasingly seek better preclinical models to predict patient responses and accelerate clinical trials. Market forces such as rising cancer immunotherapy demand, advances in 3D cell culture, and the need for more predictive in vitro systems favor NextVivo’s approach. By providing a platform that integrates immune complexity, NextVivo influences the biotech ecosystem by bridging gaps between basic immunology research and translational drug development[2][1].
NextVivo is poised to expand its platform capabilities and partnerships with pharmaceutical companies to accelerate immune therapy development. Future trends shaping its journey include advances in personalized medicine, AI-driven drug discovery, and growing emphasis on immune-oncology. As the company scales, it may broaden applications beyond oncology to infectious and autoimmune diseases, potentially becoming a key player in next-generation therapeutic testing platforms. Its influence is likely to grow as the biotech industry increasingly demands more physiologically relevant models to reduce drug development costs and improve clinical success rates[2][1].
In summary, NextVivo leverages cutting-edge immune organoid technology to transform drug development by enabling more accurate, immune-competent human tissue models, addressing critical gaps in therapy testing and accelerating innovation in immunotherapy and beyond.
NextVivo has raised $8.0M in total across 1 funding round.
NextVivo's investors include Abstract Ventures, Alumni Ventures, Andreessen Horowitz, Atomic, DFJ Growth, DST Global, General Catalyst, Khosla Ventures, Menlo Ventures, Quiet Capital, ZhenFund, Eric Ries.
